Special Issue

Fundamental Aspects of Atherosclerosis: Scientific Research for Improving the Technologies of Personalized Medicine

Message from the Guest Editor

The worldwide prevalence of atherosclerosis and associated diseases is growing on an epidemic scale. The early detection of atherosclerotic changes requires modern molecular genetic, biochemical, pathophysiological, and equipment studies, which enable a personalized approach to the choice of treatment. Personalized medicine includes a range of approaches to healthcare based on factual data: from precise molecular diagnostics to predicting the onset or development of a disease on the basis of genetic research. We are pleased to invite you to submit papers with the results of basic research on atherosclerosis aimed at improving the technologies for the prevention, diagnosis, risk assessment, and treatment of atherosclerosis from the standpoint of personalized medicine. This Special Issue aims to familiarize physicians and researchers with the latest advances in the basic research of atherosclerosis from the standpoint of personalized medicine.

Guest Editor

Prof. Dr. Yuliya I. Ragino

Institute of Internal and Preventive Medicine–Branch of Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, 630089 Novosibirsk, Russia

Deadline for manuscript submissions

closed (31 August 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/159891

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

